Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 253

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 253
---
B ASC Topic 718. A discussion of             
 the assumptions and methodologies used to calculate these amounts is contained in the notes to our financial statements under “Shareholders’ 
 Equity”. The Company issued options in April 2024 and October 2024. On October 1, 2024 some options issued in April 2024                     
 were canceled.                                                                                                                               |

151

| (2) | The amounts reported in this column                                                                                      
 represent (i) $13,200 in Company contributions made under our 401(k) plan and (ii) $2,835 in Company-paid life insurance 
 premiums during the fiscal year ended December 31, 2024.                                                                 |

| (3) | In April 2024, Mr. Ehrlich                                                                                                            
 received stock options to purchase 264 shares of common stock at $3,540.00 per share. Additionally, on October 1, 2024, Mr. Ehrlich   
 received options to purchase 1,275 shares of common stock at $200.00 per share. On October 1, 2024, the options granted in April 2024 
 were canceled pursuant to an agreement between Mr. Ehrlich and the Company.                                                           |

| (4) | In April 2024, Mr. Atwood                                                                                                                  
 received stock options to purchase 659 shares of common stock at $3,540.00 per share and 7 shares of common stock at $10,560.00 per share. 
 Additionally, on October 1, 2024, Mr. Atwood received options to purchase 254 shares of common stock at $200.00 per share.                 
 On October 1, 2024, the options granted in April 2024 were canceled pursuant to an agreement between Mr. Atwood and the                    
 Company.                                                                                                                                   |

| (5) | In April 2024, Dr. Corey                                                                                                              
 received stock options to purchase 428 shares of common stock at $3,540.00 per share. Upon his resignation, all unvested options were 
 canceled.                                                                                                                             |

| (6) | In April 2024, Mr. Carter                                                                                                             
 received stock options to purchase 198 shares of common stock at $3,540.00 per share. Upon his resignation, all unvested options were 
 canceled upon his resignation.                                                                                                        |

| (7) | On October 1, 2024, Mr. Kucharchuk                                                  
 received stock options